surmount-1 tirzepatide trial obesity without diabetes for maintenance of bodyweight reduction in people with in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled Effect of tirzepatide in SURMOUNT-1

For anyone evaluating whether the triple-agonist approach is worth the added complexity, the clinical data speaks clearly

Dose escalation side effects (recurring) Each dose increase can bring a brief return of GI symptoms

Interestingly, 10mg of tirzepatide was almost as effective as the sub-analysis revealed a -23lb (10.5kg) weight loss

Some patients using advanced metabolic therapies report: forgetting to eat, struggling to hit protein goals, lower energy during workouts, or feeling overly full throughout the day

Two to three sets of 8 to 12 repetitions per exercise, taken close to failure, provides sufficient stimulus

A 15 mg dose at 5 mg/mL would require 300 units, which is 3 mL, far more than a standard insulin syringe can hold